The factors affecting T cell reconstitution post haematopoietic cell transplantation (HCT) are not well characterised. We carried out a longitudinal analysis of T cell reconstitution in 32 HCT recipients during the first 12 months post transplant. We analysed reconstitution of naı¨ve, memory and effector T cells, their diversity and monitored thymic output using TCR rearrangement excision circles (TRECs). Thymic-independent pathways were responsible for the rapid reconstitution of memory and effector T cells less than 6 months post HCT. Thymic-dependent pathways were activated between 6 and 12 months in the majority of patients with naı¨ve T cell numbers increasing in parallel with TREC levels. Increasing patient age, chronic GVHD and T cell depletion (with or without pretransplant Campath-1H) predicted low TREC levels and slow naı¨ve T cell recovery. Furthermore, increasing patient age also predicted high memory and effector T cell numbers. The effects of post HCT immunosuppression, total body irradiation, donor leucocyte infusions, T cell dose and post HCT infections on T cell recovery were also analysed. However, no effects of these single variables across a variety of different age, GVHD and T cell depletion groups were apparent. This study suggests that future analysis of the factors affecting T cell reconstitution and studies aimed at reactivating the thymus through therapeutic intervention should be analysed in age-, GVHD-and TCD-matched patient groups.
The transplantation of allogeneic haematopoietic stem cells provides a potentially curative treatment for a variety of immunodeficiency and metabolic disorders, aplastic anaemia and haematopoietic malignancies. The success of haematopoietic cell transplantation (HCT) is determined by many parameters (reviewed in Devine et al 1 ). These include the type of haematological disorder, 2, 3 stage of disease at the time of transplant, 4 HLA matching of donor and patient and whether the donor and patient are related or unrelated, [5] [6] [7] [8] pretransplant conditioning, [9] [10] [11] [12] T cell depletion, [13] [14] [15] GVHD prophylaxis, 16 incidence and severity of GVHD, 8, 16, 17 post-transplant infections, 8, [16] [17] [18] [19] [20] [21] [22] [23] [24] patient age 25 and stem cell source (reviewed in Korbling et al 26 ) . While each of these parameters may have mutually exclusive effects on the outcome of the transplant, it is the combination of all of these parameters that will determine the ultimate success of the transplant. Furthermore, the effects of each of these parameters on immune reconstitution post HCT are unclear.
The immediate post transplant period is followed by a severe and often prolonged immune deficiency that results in prolonged susceptibility to infection. 8, 17, [19] [20] [21] [22] Although infections that occur in the first month after engraftment probably result from deficiencies in both granulocytes and other mononuclear cell subsets, the more prolonged immune deficiency arises from deficiencies in effective CD4 þ T cell and B cell reconstitution and immunosuppressive therapy. 23, [27] [28] [29] It was then suggested that the reconstitution and maintenance of effective T cell immunity after HCT was dependent on education of T cell precursors in the thymus. [30] [31] [32] Furthermore, these observations generated considerable interest in the factors affecting the reconstitution of T cell immunity through thymic-dependent pathways. 33, 34 Using phenotypic markers of T cell naivety (primarily the CD45RA antigen), initial studies demonstrated that increasing patient age had an adverse effect on the regeneration of naı¨ve CD4 þ T cells, presumably due to age-related thymic involution, 31 observations that were confirmed using the TCR rearrangement excision circle (TREC) assay to measure thymic output. 35, 36 In addition, the thymus has been demonstrated to be a target of GVHD and the presence of GVHD after HCT is associated with decreased TREC levels. 34 There is also evidence that thymic output can be influenced by donor lymphocyte infusions (DLI) 37 and pre-BMT radiotherapy. 38 The aim of this study was to carry out a comprehensive analysis of T cell subset reconstitution, thymic output and those factors that affect T cell reconstitution post HCT. We have used a combination of the TREC assay, T cell phenotyping and analysis of the TCR Vb repertoire to elucidate the contribution of thymic-dependent and thymicindependent pathways to reconstitution of the T cell compartment and have carried out an analysis of the factors affecting the utilisation of each of these pathways. To this end we have carried out a prospective, longitudinal analysis of T cell reconstitution in 32 patients during the first year post HCT.
Patients, materials and methods

Blood samples
Post-transplant blood samples were collected from patients at 3, 6, 9 and 12 months post stem cell transplant. Informed consent was obtained from all patients or their parents. The study was approved by the Royal Free Hampstead NHS Trust Ethical Practices Sub-Committee. PBMCs were separated from whole-blood samples by density gradient centrifugation using Lymphoprep (Nycomed Pharma AS, Norway). Following this, samples were either used fresh or stored in liquid nitrogen until further use.
Magnetic bead separation
PBMCs were separated into CD4 þ and CD8 þ subsets using anti-CD4-and anti-CD8-labelled MACS magnetic microbeads and MS þ /RS þ positive selection columns (Miltenyi Biotec, Germany) according to the manufacturer's instructions.
Quantification of TREC in sorted CD4 and CD8 T cells TREC frequencies were determined by real-time quantitative PCR using the 5 0 nuclease assay and an ABI7700 sequence detection system (Applied Biosystems, USA) as described previously. 36 Sorted CD4 þ and CD8 þ cells were lysed in 100 mg/ml proteinase K (Boehringer Mannheim, Germany) for at least 1 h at 561C, followed by 951C for 15 min. Real-time quantitative PCR was carried out on 5 ml of cell lysate (50 000 cells) using the primers CAC ATCCCTTTCAACCATGCT and GCCAGCTGCAGGG TTTAGG and probe FAM-5 0 -ACACCTCTGGTTTTTG TAAAGG-TGCCCACT-3 0 -TAMRA (Amersham-Pharmacia, UK). Each PCR reaction contained 0.5 U Platinum Taq polymerase (Gibco, UK), 3.5 mmol/l MgCl 2 , 0.15 mmol/l dNTPs, 500 nmol/l each primer, 150 nmol/l probe and BD636 background reference dye (Megabases, USA). Thermal cycling conditions were 951C for 5 min, then 951C for 30 s, 601C for 1 min, for 40 cycles. A standard curve was generated using predetermined standards of known concentration, and the ABI7700 software calculated TREC frequency. Absolute numbers of circulating TREC þ T cells (thymic emigrants) were calculated from absolute CD4 and CD8 counts and TREC frequency (initially expressed as TREC/100 000 T cells).
Enumeration of naïve, memory and effector T cells
Absolute CD4
þ and CD8 þ T cell counts were determined using TruCOUNT technology (Becton Dickinson, UK) according to the manufacturer's instructions. A 20 ml volume of TriTEST reagent (either CD3 FITC/CD4 PE/ CD45 PerCP or CD3 FITC/CD8 PE/CD45 PerCP) was aliquoted into a TruCOUNT tube containing a known quantity of beads. Following this, exactly 50 ml of heparinised whole blood was added and the cells were stained for 15 min at room temperature. Lysis of red blood cells was subsequently carried out by the addition of 450 ml FACS Lysing solution and incubation of samples for a further 15 min at RT. Samples were acquired using a FACScan and MultiSet software (Becton Dickinson). Absolute CD4 and CD8 cell counts were calculated automatically by the Multiset software.
Naı¨ve, memory and effector T cells in patient blood samples were detected using the following antibodies: CD3, CD4 and CD8 PerCP, CD4, CD8 and CD57 FITC, CD27 and CD28 PE (Becton Dickinson); CD45RA-PE and CD45RO-FITC (Serotec, UK). Samples were acquired using a FACScan and Cellquest software (Becton Dickinson). Naı¨ve, memory and effector cells were defined according to phenotypic and functional analyses performed previously. [39] [40] [41] Naı¨ve T cells were defined as CD4
Absolute naı¨ve T cell numbers were calculated from total T cell numbers according to the percentage of CD4 þ or CD8 þ , CD45RO
À CD27 þ cells present in each sample. The same calculation was carried out for absolute numbers of memory CD4
Analysis of T cell receptor repertoire diversity
Total RNA was extracted from 5 Â 10 5 PBMCs using the RNeasy kit from Qiagen Ltd (Qiagen, UK) according to the manufacturer's instructions. All the RNA obtained was then used to synthesise cDNA using 200 U M-MLV reverse transcriptase and random hexamers (Promega, UK). Total cDNA was divided equally between 26 PCRs. cDNA was amplified in 25 ml reactions with one of 26 TCR Vb sense primers and a TCR Cb CY5-labelled antisense primer (MWGBiotech, Germany). The final reaction mixture contained 0.25 mm of each primer, 0.25 mm dNTPs, 1 mm MgCl 2 , 2.5 ml 10 Â buffer and 1 U of Taq Polymerase (Promega, UK). PCR conditions were 951C for 1 min followed by 30 cycles of 951C for 30 s, 581C for 30 s, 721C for 1 min, with a final extension of 721C for 10 min. PCR primer sequences were as previously described. 42 A volume of 5 ml fluorescently labelled PCR product was mixed with 1 ml formamide loading buffer and run on a 6% denaturing gel at 1500 V for 10 h on an ALF Express (Pharmacia, USA). Products were analysed using the Allele links programme (Pharmacia, USA).
Spectratype complexity scoring
The complexity of the Vb subfamilies was determined by counting the number of discrete peaks per subfamily. These were graded on a score of 0-8. Normal complexity is characterised by a Gaussian distribution that reflects the presence of polyclonal cDNA. A score of 0 was given if no subfamilies were present and 1 for a single peak, etc. The overall spectratype complexity score per sample was calculated from the total number of subfamilies. The complexity score in normal individuals ranged from 142 to 208 (data not shown).
Statistical analyses
Statistical analyses were carried out using the MannWhitney U-test and Spearman's rank correlation coefficients using Prism software (GraphPad Software, USA).
Results
Patients
The demographic details of the 32 patients enrolled in this study are shown in Table 1 ; Table 2 shows those parameters that may influence T cell reconstitution, for example, T cell dose, T cell depletion, GVHD, DLI and immunosuppression. Of the 32 patients, 27 survived for the duration of the study. Clearly, this is a heterogeneous patient group encompassing a wide variety of ages and diseases. In addition, the conditioning regimens, haematopoietic cell sources, graft manipulations and post-transplant immunosuppressants vary between the individuals. Due to the relatively small number of patients in this study and the heterogeneity of the group, possible factors affecting immune reconstitution were analysed independently of other variables. Therefore, the effect of patient T-cell recovery post stem cell transplantation PR Fallen et al age was analysed regardless of whether patients received peripheral blood or bone marrow, whether the grafts were T cell depleted or not, whether patients had acute or chronic GVHD and so on.
The first priority in this study was to gain an overall picture of T cell reconstitution in this patient group by measuring the absolute number of circulating T cells. Total CD3 þ , CD4 þ and CD8 þ T cell numbers were measured at 3, 6, 9 and 12 months post HCT ( Figure 1 ).
The median number of CD3 þ T cells remained below the normal range for the first 6 months post HCT (Figure 1a There is clearly a wide range of CD3 þ , CD4 þ and CD8 þ T cell numbers in these patients after HCT with a large proportion of patients having T cell counts below the normal range 3 months post HCT. Nevertheless, the /kg. T cell dose in recipients of a T cell-depleted (TCD) donor product was defined as 'unknown'. d GVHD: acute GVHD was defined as grades I-IV; Chronic GVHD was defined as L ¼ limited or E ¼ extensive; N ¼ no clinical GVHD. e GVHD prophylaxis: cyclosporin A (CsA) was administered on day À1 and patients remained on CsA for a period of 3 (CsA 3 ) or 12 (CsA 12 ) months; methotrexate (Mtx) was administered on days +1, +3 and +6. f Patient suffered allergic reaction to CsA and was placed on either FK506 or mycophenolate (Myco) as alternative immunosuppressive therapy. g Patients undergoing episodes of either acute or chronic GVHD were treated with one or more of the following: Prednisolone, Methylprednisolone, Mycophenolate, with additional immunosuppression using CsA as deemed appropriate by the clinician. h Additional GVHD therapy included Psoralen-activated ultraviolet A phototherapy (PUVA). majority of patients restore T cell counts to within the normal range by 12 months post HCT. However, absolute CD4 þ and CD8 þ cell counts give little information on the origin of these cells. We therefore attempted to delineate the contribution of thymic-dependent and thymic-independent pathways to T cell recovery post HCT.
Thymic output, naïve, memory and effector T cell reconstitution
Thymic output (as determined by TREC measurements) and naı¨ve, memory and effector T cell recovery for our cohort of patients is summarised in Table 3 . TREC were low in both CD4 þ and CD8 þ subsets 3 months post transplant (median CD4 TREC/ml ¼ 0.1 (range: 0-4); median CD8 TREC/ml ¼ 0.1 (range: 0-39)) and increased with increasing time post HCT. Absolute numbers of naı¨ve
T cells were also low during the first 3 months post HCT and increased in parallel with TREC levels with increasing time post HCT. The recovery of naı¨ve CD4 þ and CD8 þ T cells correlates with increasing TREC levels (data not shown). This observation suggests that recovery of naı¨ve T cell numbers post HCT is reliant on thymic maturation of T cell precursors and is not a result of peripheral expansion of naı¨ve, graft-derived T cells or reversion of memory T cells to a naı¨ve phenotype.
In contrast to the slow reconstitution of naı¨ve T cells and absolute TREC numbers, memory and effector T cell numbers increased rapidly (o3 months post HCT). This expansion was much more pronounced in the CD8 þ compartment than in the CD4 þ compartment with a number of patients reconstituting very high levels of CD8 cells. This CD8 'overshoot' has been observed previously 30, 43, 44 but the exact mechanism is unclear at present. This very likely represents homeostatic expansion of graftderived T cells, a phenomenon that has been extensively described in irradiation-induced or genetically lymphopenic mice. Furthermore, these results confirm previous observations that T cell numbers are restored in the short-term post HCT via peripheral expansion of graft-derived mature T cells.
Factors affecting T cell reconstitution
The factors influencing the utilisation of thymic-dependent and thymic-independent pathways post HCT were assessed. Due to the relatively small number of patients in this study, these were analysed as single variables (see Materials and methods).
Effect of patient age on thymic output and naïve T cell recovery
It is well documented that the thymus involutes as part of the normal ageing process, and that this involution is paralleled by a gradual decrease in production of thymic emigrants with increasing age. 35, [45] [46] [47] [48] [49] Therefore, the effect of patient age on thymic ouput and recovery of T cell subsets after HCT was assessed.
The patients detailed in Tables 1 and 2 were divided into two groups with the first group ranging from 6 to 30 years old (n ¼ 13) and the second group ranging from 30 to 53 years old (n ¼ 19). The groups were divided in this way simply to have significant numbers within each group since previous reports described a linear decline in TREC levels throughout life. 35 There was no significant difference in CD4 or CD8 TREC levels between the two age groups 3 The differences in TREC levels between the two age groups were statistically significant at 6, 9 and 12 months for CD4 TREC (P ¼ 0.019, P ¼ 0.014, P ¼ 0.004, respectively), and 12 months post HCT for CD8 TREC (P ¼ 0.003). Therefore, when age alone was taken into consideration, there was a significant adverse effect of increasing age on thymic output in these patients. The effect of increasing age on naı¨ve T cell recovery was also analysed. There was no statistically significant difference between numbers of naı¨ve T cells in the two patient groups over the first 9 months post transplant (Figure 2c and d) . However, by 12 months post transplant, there were significantly more naı¨ve CD4 þ and CD8
þ T cells in the younger patient group compared to the older patient group (P ¼ 0.0005 and P ¼ 0.001, respectively).
Effect of GVHD on thymic output and naïve T cell recovery
A previous study using TREC to measure thymic output demonstrated that GVHD had an adverse effect on thymic output. 34, 50 Therefore, TREC levels in sorted CD4 þ ( Figure 3a ) and CD8 þ (Figure 3b ) cells were measured in patients who had no episodes of GVHD (n ¼ 22) or patients who had experienced or were experiencing ongoing chronic GVHD (n ¼ 9). TREC levels in patients with no GVHD were low or undetectable for the first 6 months post HCT (median CD4 TREC ¼ 0.12 (0-6.8); median CD8 TREC ¼ 0.13 (0-9.8)). The majority of patients experienced increases in TREC levels between 6 and 12 months post HCT. By contrast, patients experiencing ongoing episodes of chronic GVHD did not experience a rise in TREC levels at any time point (median CD4 and CD8 TREC levels were less than 0.1 TREC per microlitre blood at all time points). The difference in CD4 and CD8 TREC levels between patients with or without chronic GVHD was statistically significant 9 and 12 months post HCT for CD4 þ T cells (P ¼ 0.0016 and P ¼ 0.006, respectively) and 12 months post HCT for CD8 þ T cells (P ¼ 0.015). The effects of GVHD on naı¨ve T cell recovery also do not become apparent until 12 months post transplant in the majority of patients. Naı¨ve CD4 þ and CD8 þ T cell counts at 12 months post-transplant were significantly reduced in patients experiencing chronic GVHD compared to patients without GVHD (Figure 3c and 3d ).
Other factors affecting thymic output and naïve T cell reconstitution post HCT
Recipients of T cell-depleted grafts had significantly reduced CD4 and CD8 TREC levels 3 and 6 months post HCT compared with recipients of T cell-replete grafts (P ¼ 0.03 and P ¼ 0.01, respectively, for CD4 TREC and P ¼ 0.02 and P ¼ 0.03, respectively for CD8 TREC; data not shown). This reduction in TREC numbers was also reflected in naı¨ve T cell recovery. Naı¨ve CD4 þ and CD8 þ T cell numbers were significantly reduced in recipients of T cell-depleted grafts compared with recipients of T cellreplete grafts at 3, 6 and 9 months (P ¼ 0.0004, P ¼ 0.0005, P ¼ 0.04, respectively for naı¨ve CD4 þ T cells and P ¼ 0.0016, P ¼ 0.016, P ¼ 0.04, respectively for naı¨ve CD8 þ T cells). The effects on TREC levels and naı¨ve T cell numbers of T cell dose (in T cell-replete HCT recipients), stem cell source (PB vs BM), DLI, TBI, administration of Campath-1H and post-HCT immunosuppression were also analysed. Patients who received Campath-1H, either 'in-the-bag' as part of their TCD protocol or who received Campath-1H as part of their pretransplant conditioning regimen (detailed in Table 1) , were compared with patients who did not receive any Campath-1H. Campath-1H administration resulted in Table 3 Thymic output and recovery of naı¨ve, memory and effector T cell subsets reduced numbers of naı¨ve T cells during the first 3 months post transplant (data not shown). However, no differences were seen thereafter. Campath-1H administration had no effect on TREC levels at any time post transplant. None of the remaining transplant-related factors had a significant effect on TREC levels or naı¨ve T cell numbers at any time point in this patient cohort. Of note, there was no difference in naı¨ve T cell numbers or TREC levels between patients who received Cyclosporin A for 3 or 12 months post transplant suggesting that thymic output is unaffected by this immunosuppressive agent. It may be that the small number of patients in this study prevented the results reaching statistical significance. Alternatively, all of these factors were analysed in patient groups that included a variety of different age, GVHD and T cell-depletion groups. It may be that the effects of age and GVHD (and possibly also T cell depletion) on TREC and naı¨ve T cell numbers masked any effects of these other factors. A multivariate analysis was not possible in this study.
Factors predicting the utilisation of thymic-independent pathways of T cell reconstitution post HCT
Previous studies demonstrated that T cell recovery post HCT is almost exclusively of cells with a memory or effector T cell phenotype in the short term. This observation suggests that the initial phase of T cell engraftment is primarily due to the proliferation of mature T cells in the stem cell graft rather than the differentiation of new T cells from haematopoietic progenitors. The recovery of T cell function (as opposed to T cell numbers) is thought to be reliant on the recovery, via thymic-dependent pathways, of a diverse pool of naı¨ve T cells. 30, 32 Nevertheless, populations of memory and effector cells are almost certainly required to provide some protection against opportunistic infections in the short term after transplant.
Effect of patient age on reconstitution of memory and effector T cells
The results from this study demonstrated an inverse relationship of patient age with recovery of naı¨ve T cells. It is also known that naı¨ve T cell numbers decrease and memory T cell numbers increase as part of the normal ageing process. 51, 52 Therefore, the effect of patient age on the recovery of memory and effector T cells after HCT was assessed (Figure 4) .
The older patient group (30-53 years-old) had a significantly higher median number of memory CD4 þ T cells 3 months post HCT (median ¼ 126 (14-568) cells per ml) compared with the younger (6-30 years-old) patient group (median ¼ 44 (10-539) cells per ml); (P ¼ 0.006). However, there were no significant differences in memory CD4 þ T cell numbers between the two groups at any other time point after transplant. The median number of nonnaı¨ve CD8 þ T cells was also significantly higher in the 30-53 year-old patient group at 3 months post HCT (median ¼ 573 (48-3699) compared with the 6-30 year-old patient group (median ¼ 94 (10-973); (P ¼ 0.002). This difference was maintained throughout the first year post HCT. Analysis of the more differentiated effector-type
revealed that the median number of these cells was also higher in the older (30-53 year-old) patient group at all time points. This was statistically significant at 3, 6 and 12 months post transplant (P ¼ 0.01, 0.02 and 0.03, respectively for CD4 þ effector T cells and P ¼ 0.003, 0.042 and 0.025, respectively for CD8 þ CD57 þ CD28 À T cells). From these data, it appears that there are higher numbers of CD4 þ and CD8 þ T cells that display a memory or effector phenotype in older individuals after HCT. These data are consistent with the notion that thymic-independent pathways are able to restore T cell numbers when thymic output is absent or reduced. Whether a feedback mechanism exists whereby signals from an active, noninvoluted thymus (whether they be cellular or soluble) inhibit proliferation and expansion of memory and effector T cells is intriguing, but not proven as yet. Studies by Mackall et al 53, 54 demonstrated that peripheral expansion is increased in athymic T cell-depleted mice compared to thymus-bearing T cell-depleted mice. Furthermore, subsequent analysis showed that this increased peripheral expansion in athymic hosts was a direct result of the absence of thymic emigrants. 53 It is possible that the same mechanism is active in the patients described in the present study.
Other factors affecting reconstitution of memory and effector cell reconstitution post HCT
The effects of GVHD, T cell depletion, T cell dose, stem cell source, TBI, immunosuppression, Campath-1H and post HCT infections on memory and effector T cell reconstitution were analysed. Similar to naı¨ve T cell reconstitution, administration of Campath-1H, either 'in-the-bag' or as part of the pretransplant conditioning regimen predicted low numbers of memory and effector T cells 3 months post transplant compared with patients who did not receive Campath-1H. Again, no effect was noted thereafter. None of the remaining factors had a significant effect on memory or effector cell reconstitution post HCT.
Analysis of TCR VB repertoire
The previous results demonstrate differences in the quantity and quality of the reconstituting T cells in different individuals. However, these values do not provide information on the complexity of the T cell repertoire in these individuals. The restoration of a diverse, self-restricted T cell repertoire is essential for transplant recipients to maintain a normal functioning immune system. We therefore analysed the changes in TCR diversity by spectratyping of the TCR Vb chain and scored the complexity of the repertoire.
In a normal individual, the spectratype complexity score, based on the total number of peaks in a Gaussian distribution, is between 142 and 208, with the individual having an average of 8 peaks per TCR Vb chain. The measurement of peaks in this way allowed us to compare the diversification between the different patient groups outlined previously. The previous data demonstrated adverse effects of increasing age and chronic GVHD on regeneration of naı¨ve T cells. We were able to obtain TCR repertoire data from 19 patients out of the 32 described in Tables 1 and 2 . These were further subdivided into three groups, children (o18 years of age; n ¼ 7), adults (418 years of age; n ¼ 6) and adults with chronic GVHD (n ¼ 6).
The average range of TCR diversity in the children, adults with no GVHD and adults with GVHD based on the change in number of peaks over time is shown in Figure 5 . The children have a rapid rate of receptor diversification and the spectratyping profile develops a normal Gaussian distribution by 12 months post transplant. Representative profiles illustrating the change in repertoire in one patient from each group is shown in Figure 6 . In the adults with no GVHD, the complexity of the repertoire increases over time but does not diversify to the same extent as the children by 12 months post transplant. The adults who have chronic GVHD do not experience a significant diversification of the TCR Vb repertoire over the first 12 months post transplant, which very likely reflects the lack of thymic output in these patients. The increasing diversity of the Vb repertoire in the children in this study significantly correlates with increasing TREC numbers (r ¼ 0.80, P ¼ 0.0002 for CD4 TREC; r ¼ 0.74, P ¼ 0.001 for CD8 TREC).
Discussion
The results presented in this study demonstrate that (1) total CD3 þ , CD4 þ and CD8 þ T cells recover to within normal limits in the majority of patients between 6 and 9 months post HCT; (2) memory and effector T cells are reconstituted rapidly (less than 6 months post HCT) with naı¨ve T cells recovering later between 6 and 12 months post HCT; (3) although thymic output could be detected 3 months post HCT, the majority of patients did not experience rises in TREC levels until after 6 months post HCT; (4) increasing patient age is predictive of low thymic output, slow naı¨ve T cell recovery and increased reconstitution of memory and effector T cells; (5) patients with chronic GVHD had profoundly reduced TREC levels and reduced naı¨ve T cell reconstitution compared to patients with no history of GVHD; (6) adults and children with no history of GVHD recover a TCR repertoire within normal limits, whereas patients with ongoing chronic GVHD remain restricted during the first 12 months post HCT; (7) other factors affecting T cell reconstitution were not significant when analysed across different age and GVHD groups.
The recent development of the TREC assay has generated a great deal of interest in T cell reconstitution by thymic-dependent pathways and the factors affecting this pathway. Furthermore, this assay has given investigators a convenient tool with which to monitor strategies aimed at reactivating the thymus.
The results presented here confirm previous suggestions 34, 50 that age alone is a crucial factor determining the contribution of thymic output to T cell recovery post HCT. Furthermore, our results suggest that patient age may be the single most important factor determining the success of immune reconstitution post HCT and whether thymicdependent or thymic-independent pathways contribute to the process of T cell reconstitution post HCT. An agerelated decline in T cell function has been described in a variety of clinical settings [55] [56] [57] [58] [59] and as part of the normal ageing process. [60] [61] [62] This decline in T cell function has been linked to the involution of the thymus that begins as early as 1 year of age and continues throughout life. [63] [64] [65] Although several hypotheses have been put forward to explain age-related thymic involution (reviewed in George and Ritter 63 ), the exact mechanism remains unclear. Nevertheless, the effect of increasing age on reduced TREC levels in this study is almost certainly related to ageassociated thymic involution.
Patients who experienced ongoing episodes of chronic GVHD with or without prior acute GVHD did not experience a rise in TREC levels, and as a result did not reconstitute the naı¨ve T cell compartment for the duration of the study. This suggests that either chronic GVHD or the immunosuppressive drugs used in its treatment have an adverse effect on thymic output.
It is essential to the development of a diverse T cell compartment, with the capability of responding to thousands of environmental antigens that both thymic-dependent and thymic-independent pathways work together. Therefore, in situations where one of the pathways is compromised, for example, loss of thymic output in patients with chronic GVHD, the recovery of a normal diverse T cell compartment could be delayed, possibly for many years after transplant. The lack of production of TREC þ T cells in patients with ongoing chronic GVHD suggests that either GVHD-mediated thymus damage, immunosuppressive therapy or both causes a shutdown in thymopoiesis. It is well documented that the thymus is a target organ in GVHD and it has also become apparent over the last decade that thymic damage by alloreactive T cells may play an important part in the pathology and development of GVHD. [66] [67] [68] [69] [70] [71] The impact of GVHD on the immune system in post transplant patients includes T cell lymphopenia with prolonged immunodeficiency and lack of appropriate thymic education which results in the appearance of autoreactive T cell clones. 67, 69, [71] [72] [73] [74] The results from our study together with the evidence of GVHD-mediated thymus damage indicate that the thymus is unable to contribute to T cell reconstitution in post transplant patients with chronic GVHD. Interestingly, there is some evidence that upon resolution of GVHD, thymic architecture can be restored and thymic education of T cell progenitors is able to take place. 66, 75 This may allow therapeutic intervention aimed at reactivating thymic-dependent pathways after resolution of GVHD.
It is also possible that steroid treatment and immunosuppressive drugs used in the treatment of GVHD also have an adverse effect on thymic output. There are numerous in vivo and in vitro reports on corticosteroids and their analogues which effect thymocyte apoptotsis and which also have adverse effects on peripheral T cell activation events. [76] [77] [78] [79] [80] [81] [82] However, a previous study by Wienberg et al 34 demonstrated that TREC levels increased in cord blood transplant recipients even while receiving low-dose steroids as GVHD prophylaxis. However, this data does not exclude the possibility that high dose corticosteroids used in GVHD treatment would have an adverse effect on thymic output. The observation that CD4 and CD8 TREC levels were significantly lower in recipients of T cell-depleted grafts compared with recipients of T cell-replete grafts raises one of the limitations of this study and the TREC assay in general. It is probable that TREC þ T cells are transferred with the haematopoietic cell graft. However, it is not possible to separate de novo generated TREC þ T cells from TREC þ T cells that are transferred with the graft. Therefore, it is possible that the differences in TREC levels between recipients of T cell-depleted and T cell-replete grafts reflect depletion of TREC þ T cells from the graft. However, it is also possible that the lack of TREC detected in TCD recipients reflects the ongoing reconstitution of the T cell compartment by expansion of small numbers of graft-derived T cells (0-5 Â 10 5 T cells/kg, depending on the method of TCD employed 14, 15, [83] [84] [85] [86] and/ or recent thymic emigrants. Therefore, when a TREC þ thymic emigrant is produced during the early stages post transplant in T cell-depleted graft recipients, it may be subjected to the same homeostatic pressure as the other peripheral T cells and be stimulated to proliferate. If this were to occur on a larger scale, the detection of TREC molecules and naı¨ve T cells would not be enabled until a threshold number of T cells is reached and homeostatic proliferation returns to normal levels. In contrast to the extremely lymphopenic environment in a TCD transplant recipient, recipients of T cell-replete grafts often receive grafts containing large numbers of T cells and are less reliant on homeostatic proliferation to restore T cell numbers. This would subsequently enable naı¨ve T cell and TREC detection earlier after transplant than recipients of T cell-depleted grafts. However, it should be noted that while these processes may be operative, the proof of such a hypothesis would require in vivo data. There is no direct evidence that this is the case other than the fact that TREC detection is possible at 3 months post transplant in T cellreplete HCT recipients but is delayed until 6-9 months post transplant in recipients of T cell-depleted grafts.
Since the early post transplant period is characterised by a profound immunodeficiency, it should be beneficial to the transplant recipient to rapidly reconstitute a fully functional immune system. The recovery of a self-restricted, diverse T cell repertoire is dependent on thymic production of T cells from haematopoietic progenitors. Therefore, it is necessary to consider therapeutic approaches that would facilitate faster immune reconstitution in recipients of HCT. It is known that GVHD is detrimental to both thymic-dependent and thymic-independent pathways, therefore GVHD prevention (with the maintenance of the GvL effect) remains an important goal. Since the adult thymus is still capable of producing new T cells, there is the potential to increase thymic output by intervention with therapeutic agents. A number of studies have demonstrated increased thymopoiesis by administration of IL-7. 54, [87] [88] [89] IL-7 has been shown in these studies to reduce thymocyte apoptosis, normalise thymic cellularity and as a consequence, increase thymic output. Other agents that may have a protective effect against or reverse thymic involution include leptin, 90 tamoxifen, 91 tachykinins 92 and a combination of keratinocyte growth factor (KGF) and IL-7. 93 In conclusion, this study has demonstrated that patient age, GVHD and T cell depletion have a significant effect on T cell reconstitution post HCT. Furthermore, the influence of these factors was so dominant that the effect was apparent across a diverse group of patients. It is of course possible that other factors such as TBI, and immunosuppression influence T cell reconstitution, but these effects may be more subtle than age, GVHD and T cell depletion. Future studies should address these issues in age-, GVHDand T cell depletion-matched patient cohorts.
